Opioidergic: Difference between revisions
Content deleted Content added
m →Allosteric modulators: Task 1d: Fix CS1 deprecated date parameter errors |
No edit summary |
||
| (24 intermediate revisions by 21 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Classification of chemicals that directly modulate opioid neuropeptide systems}} |
|||
{{Main article|Opioid}} |
|||
[[File:Correlación estructural entre las encefalinas y la morfina.svg|thumb|260px|Structural correlation between [[met-enkephalin]], an opioid peptide, ''(left)'' and [[morphine]], an opiate drug, ''(right)'']] |
|||
'''Opioidergic''', or simply '''opioid''', means "related to [[opioid]]s". |
|||
An '''opioidergic agent''' |
An '''opioidergic agent''' (or '''drug''') is a chemical which directly or indirectly modulate the function of [[opioid receptor]]s. Opioidergics comprise [[opioid]]s, as well as [[allosteric modulator]]s and [[enzyme]] affecting agents like [[enkephalinase inhibitor]]s. |
||
==Allosteric modulators== |
==Allosteric modulators== |
||
[[File:BMS-986121.png|thumb|right|210px|BMS-986121]] |
[[File:BMS-986121.png|thumb|right|210px|BMS-986121]] |
||
* BMS-986121: μ-PAM<ref name="pmid23754417">{{cite journal | |
* BMS-986121: μ-PAM<ref name="pmid23754417">{{cite journal |vauthors=Burford NT, Clark MJ, Wehrman TS, etal |title=Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=110 |issue=26 |pages=10830–5 |date=June 2013 |pmid=23754417 |pmc=3696790 |doi=10.1073/pnas.1300393110 |bibcode=2013PNAS..11010830B |doi-access=free }}</ref> |
||
* BMS-986122: μ-PAM<ref name="pmid23754417"/> |
* BMS-986122: μ-PAM<ref name="pmid23754417"/> |
||
* |
* BPRMU191: confers agonistic properties to small-molecule morphinan antagonists<ref name="pmid39025070">{{cite journal |vauthors=Huang YH, Lin SY, Ou LC et al. |title=Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia |journal=Cell Chem Biol |volume=31 |issue=11 |pages=1885–1898.e10 |date=2024 |pmid=39025070 |doi=10.1016/j.chembiol.2024.06.013 |url=}}</ref> |
||
* Ignavine<ref name="pmid27530869">{{cite journal |vauthors=Ohbuchi K, Miyagi C, Suzuki Y, Mizuhara Y, Mizuno K, Omiya Y, Yamamoto M, Warabi E, Sudo Y, Yokoyama A, Miyano K, Hirokawa T, Uezono Y |title=Ignavine: a novel allosteric modulator of the μ opioid receptor |journal=Sci Rep |volume=6 |pages=31748 |date=August 2016 |pmid=27530869 |pmc=4987652 |doi=10.1038/srep31748 |bibcode=2016NatSR...631748O }}</ref> |
|||
* [[Oxytocin]]: μ-PAM<ref name="pmid29716811">{{cite journal |vauthors=Meguro Y, Miyano K, Hirayama S, et al |title=Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |journal=J. Pharmacol. Sci. |volume=137 |issue=1 |pages=67–75 |date=May 2018 |pmid=29716811 |doi=10.1016/j.jphs.2018.04.002 |doi-access=free }}</ref> |
|||
* δ-PAM (see reference)<ref name="pmid25901762">{{cite journal |vauthors=Burford NT, Livingston KE, Canals M, Ryan MR, Budenholzer LM, Han Y, Shang Y, Herbst JJ, O'Connell J, Banks M, Zhang L, Filizola M, Bassoni DL, Wehrman TS, Christopoulos A, Traynor JR, Gerritz SW, Alt A |title=Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the δ-Opioid Receptor |journal=J. Med. Chem. |volume= 58|issue= 10|pages= 4220–9|year=2015 |pmid=25901762 |doi=10.1021/acs.jmedchem.5b00007 |pmc=4703104}}</ref> |
|||
* [[Cannabidiol]]<ref name="PMID16489449">{{cite journal |vauthors=Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E | title = Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors | journal = Naunyn-Schmiedeberg's Arch. Pharmacol. | volume = 372 | issue = 5 | pages = 354–61 | date = February 2006 | pmid = 16489449 | doi = 10.1007/s00210-006-0033-x | s2cid = 4877869 }}</ref> |
|||
* [[Tetrahydrocannabinol]]<ref name="PMID16489449"/> |
* [[Tetrahydrocannabinol]]<ref name="PMID16489449"/> |
||
* [[Sodium]] (Na<sup>+</sup>) <ref name="pmid25073009">{{cite journal |vauthors=Shang Y, LeRouzic V, Schneider S, Bisignano P, Pasternak GW, Filizola M |title=Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions |journal=Biochemistry |volume=53 |issue=31 |pages=5140–9 |year=2014 |pmid=25073009 |doi=10.1021/bi5006915 |pmc=4131901}}</ref> |
|||
==See also== |
==See also== |
||
{{col div|colwidth=20em}} |
|||
* [[List of opioids]] |
|||
* [[Adenosinergic]] |
|||
* [[Adrenergic]] |
|||
* [[Cannabinoidergic]] |
|||
* [[Cholinergic]] |
* [[Cholinergic]] |
||
* [[Dopaminergic]] |
|||
* [[GABAergic]] |
* [[GABAergic]] |
||
* [[Glycinergic]] |
|||
* [[Histaminergic]] |
* [[Histaminergic]] |
||
* [[Melatonergic]] |
|||
* [[Monoaminergic]] |
* [[Monoaminergic]] |
||
* [[Serotonin|Serotonergic]] |
|||
{{colend}} |
|||
==References== |
==References== |
||
{{Reflist|2}} |
{{Reflist|2}} |
||
{{Opioidergics}} |
{{Opioidergics}} |
||
{{Neuromodulation}} |
|||
[[Category:Nervous system]] |
|||
[[Category:Neurochemistry]] |
[[Category:Neurochemistry]] |
||
[[Category:Neurotransmitters]] |
[[Category:Neurotransmitters]] |
||
Latest revision as of 16:39, 26 November 2024
An opioidergic agent (or drug) is a chemical which directly or indirectly modulate the function of opioid receptors. Opioidergics comprise opioids, as well as allosteric modulators and enzyme affecting agents like enkephalinase inhibitors.
Allosteric modulators
[edit]
- BMS-986121: μ-PAM[1]
- BMS-986122: μ-PAM[1]
- BPRMU191: confers agonistic properties to small-molecule morphinan antagonists[2]
- Ignavine[3]
- Oxytocin: μ-PAM[4]
- δ-PAM (see reference)[5]
- Cannabidiol[6]
- Tetrahydrocannabinol[6]
- Sodium (Na+) [7]
See also
[edit]References
[edit]- ^ a b Burford NT, Clark MJ, Wehrman TS, et al. (June 2013). "Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor". Proc. Natl. Acad. Sci. U.S.A. 110 (26): 10830–5. Bibcode:2013PNAS..11010830B. doi:10.1073/pnas.1300393110. PMC 3696790. PMID 23754417.
- ^ Huang YH, Lin SY, Ou LC, et al. (2024). "Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia". Cell Chem Biol. 31 (11): 1885–1898.e10. doi:10.1016/j.chembiol.2024.06.013. PMID 39025070.
- ^ Ohbuchi K, Miyagi C, Suzuki Y, Mizuhara Y, Mizuno K, Omiya Y, Yamamoto M, Warabi E, Sudo Y, Yokoyama A, Miyano K, Hirokawa T, Uezono Y (August 2016). "Ignavine: a novel allosteric modulator of the μ opioid receptor". Sci Rep. 6: 31748. Bibcode:2016NatSR...631748O. doi:10.1038/srep31748. PMC 4987652. PMID 27530869.
- ^ Meguro Y, Miyano K, Hirayama S, et al. (May 2018). "Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator". J. Pharmacol. Sci. 137 (1): 67–75. doi:10.1016/j.jphs.2018.04.002. PMID 29716811.
- ^ Burford NT, Livingston KE, Canals M, Ryan MR, Budenholzer LM, Han Y, Shang Y, Herbst JJ, O'Connell J, Banks M, Zhang L, Filizola M, Bassoni DL, Wehrman TS, Christopoulos A, Traynor JR, Gerritz SW, Alt A (2015). "Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the δ-Opioid Receptor". J. Med. Chem. 58 (10): 4220–9. doi:10.1021/acs.jmedchem.5b00007. PMC 4703104. PMID 25901762.
- ^ a b Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E (February 2006). "Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors". Naunyn-Schmiedeberg's Arch. Pharmacol. 372 (5): 354–61. doi:10.1007/s00210-006-0033-x. PMID 16489449. S2CID 4877869.
- ^ Shang Y, LeRouzic V, Schneider S, Bisignano P, Pasternak GW, Filizola M (2014). "Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions". Biochemistry. 53 (31): 5140–9. doi:10.1021/bi5006915. PMC 4131901. PMID 25073009.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |